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Abstract
Objective and design: The endoscopic technique has been recently introduced in the field of transsphe-
noidal pituitary surgery. This technique allows inspection of sellar, supra- and parasellar structures
and removal of the tumor under direct visualization, is minimally traumatic and permits easier reo-
perations. This is the first report on the results of endoscopic surgery for patients with Cushing’s dis-
ease. Our aim was to retrospectively analyze the results of pituitary surgery in 35 consecutive patients
with Cushing’s disease operated in our hospital after the introduction of the endoscopic technique
(1998–2004).
Methods: Remission was defined as suppression of plasma cortisol (#50nmol/L) after 1mg dexa-
methasone overnight determined in the first 3 months after surgery and disappearance of clinical
signs and symptoms of hypercortisolism. The patients were followed for an average of 27 months
(range 4 to 81 months, median 20 months).
Results: Pituitary MRI showed a macroadenoma in 6 patients, a microadenoma in 17 patients and no
adenoma in 12 patients. After the initial surgery 27 patients (77%) were in remission. None of the
patients had a relapse during follow-up. In the remaining 8 patients hypercortisolemia persisted
after surgery. Three of them had a second endoscopic pituitary surgery resulting in remission in
two patients. In one patient a second endoscopic pituitary surgery will soon follow. The remaining
four patients were treated with radiotherapy postoperatively. Two of them were at the time of data
collection in remission. One patient from the remission group had a serious epistaxis and three
patients had cerebrospinal fluid leakage, one requiring an external lumbar drain, shortly after sur-
gery. No complications were recorded in the failure group. Postoperatively 34% of all patients required
substitution with levothyroxine, 40% required substitution with glucocorticoids, 17% received estro-
gens or testosterone and 6% still required desmopressin.
Conclusions: Endoscopic transsphenoidal pituitary surgery resulted in our series of patients with Cush-
ings disease in an excellent postoperative remission rate. A randomized clinical trial, comparing endo-
scopic and conventional pituitary surgery in patients with Cushings disease, is needed to determine
the pros and cons of both techniques.
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Introduction
Hypersecretion of ACTH by a pituitary adenoma (Cush-
ing’s disease) is the most common cause of endogenous
hypercortisolism. The condition is potentially life threa-
tening and requires aggressive therapy. Transsphenoi-
dal pituitary microsurgery is the treatment of choice
for these patients. However, even in experienced
hands no more than 50 to 90% of patients are in remis-
sion after surgery (1–15). This may be due to the fact
that ACTH producing adenomas are small and thus
cannot be visualized, even with modern imaging tech-
niques, making it difficult for the surgeon to find the
adenoma. Moreover, hypercortisolemic patients are
prone to complications during surgery (16). Long-
term follow-up has shown that the quality of life of
patients with Cushing’s disease who are in remission
after a first pituitary operation is better than in those
patients who need additional treatment (17). Therefore,
a successful initial pituitary operation is highly desir-
able for patients with Cushing’s disease.
The endoscopic technique has been recently intro-
duced in the field of pituitary surgery (18–23).
Traditional surgical approaches to pituitary tumors
are based on transseptal or sublabial transsphenoidal
access to the sella turcica (20). The endoscopic
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endonasal approach avoids transseptal dissection, thus
reducing patient discomfort and postoperative pain.
The endoscope has increasingly been used in pituitary
surgery since the mid 1990s either in conjunction
with the microscopic technique (24) or as a pure endo-
scopic procedure (18, 25, 26). Especially the better
panoramic visualization of sellar, supra- and parasellar
anatomy with increased illumination and magnification
are recognized as major advantages offered by the endo-
scopic technique (21, 25, 27). Some concerns have
been raised regarding the lack of stereoscopic view
with the endoscope and the lack of maneuverability as
surgeons can only manipulate tools with one hand
unless a holder is used, which in turn may crowd the
operative field (19, 27, 28). These disadvantages can,
however, be reduced by using more refined instrumen-
tation (19, 27). Initial reports showed a decrease in
postoperative discomfort and hospitalization time as
well as a quick recovery in patients operated by the
endoscopic technique in comparison with the conven-
tional microscopic technique (25, 29–31). Decreased
operative time and decreased blood loss as compared
with open transsphenoidal surgery have also been
reported (31–33). The endoscopic approach is safe, all
authors reporting low complication rates (25, 26,
30–35). It is minimally traumatic and permits easier
reoperations (18–21, 23). This makes the endoscopic
pituitary approach attractive for patients with Cush-
ing’s disease in an attempt to avoid bleeding compli-
cations that are particularly feared because of the
hypercortisolemic status.
To our knowledge, there are no specific studies on the
results of endoscopic pituitary surgery in patients with
Cushing’s disease. Endoscopic pituitary surgery was
introduced in our hospital in 1997 and it has been
applied in all patients with Cushing’s disease treated in
our centre since 1998. The aim of our study was to ana-
lyze retrospectively the results of pituitary surgery in the
35 consecutive patientswith Cushing’s diseasewhohave
been operated in our hospital after the introduction of
the endoscopic technique (1998–2004).
Patients and methods
Patients
The medical records of the 35 consecutive patients with
Cushing’s disease undergoing endoscopic pituitary sur-
gery in our hospital between 1998 and 2004 were ana-
lyzed. There were 25 females and 10 males, age at the
time of diagnosis was 41.0^14.8 years and BMI was
28.7^5.3 kg/m2. We collected data on the preoperative
and the early postoperative evaluation, on compli-
cations that occurred during the operation or in the
early postoperative period and on the last evaluation
at the most recent follow-up visit.
Preoperative evaluation
Diagnosis of hypercortisolism was based on clinical
grounds and biochemical tests including repeated
24-h urinary free cortisol (UFC) measurements, assess-
ment of the circadian rhythm of plasma cortisol with
midnight plasma cortisol measurement and determi-
nation of plasma cortisol after overnight low dose dexa-
methasone (1mg at 2300h) (36). Pituitary imaging by
MRI with i.v. contrast (gadolineum) was performed in
all patients. Six of the 35 patients had a macroadenoma
(defined as $1 cm in diameter) on the preoperative
MRI. In the other patients the MRI showed either a
tumor ,1 cm (17 patients) or no evidence of a tumor
(12 patients). In addition, the results of the CRH test
(100mg human CRH i.v.) (37), and the high-dose dexa-
methasone test (7mg dexamethasone in 7 hours i.v.)
(38) were used to demonstrate the pituitary origin of
the hypercortisolism. In 12 patients bilateral catheteri-
sation of the inferior petrosal sinuses was performed
with blood sampling before and after i.v. stimulation
with 100mg human CRH (39), to confirm the pituitary
origin of the hypercortisolism in all 12 patients.
Treatment with cortisol lowering agents
before surgery and with glucocorticoids
in the perioperative period
Treatment with cortisol lowering agents, metyrapone
and/or ketoconazole, was given in 30 patients for a
period of 4 months preoperatively. On the day of sur-
gery, administration of glucocorticoids i.v. was started
(prednisolone, 25mg every 8 h i.v. for two days) with
the first dose one hour before the start of the operation.
Thereafter, the dose of glucocorticoids was decreased
rapidly (prednisolone orally 50mg on day 2, 25mg
on day 3 and 4) during the next days so that the
patients received the last dose of glucocorticoids as
10mg prednisolone orally on the fifth day postopera-
tively. Thereafter, no further glucocorticoids were admi-
nistered until the seventh day postoperatively, after
blood sampling for the first endocrine evaluation. The
interval between the last dose of glucocorticoids and
the first postoperative measurement of fasting plasma
cortisol was at least 48 h.
Surgical technique
Our technique is based on the pioneering work of Jho
et al. (22, 23) and Cappabianca et al. (18, 19). However,
we (EJvL and JAG) modified the technique by using a
binostril, transsphenoidal, endoscopic approach to the
sella turcica with a handheld endoscope.
The optic instrument used was a 58 lensscope with a
diameter of 4mm and a separate shaft around it for irri-
gation and suction to clear the front lens. This instru-
ment allows by its pistol grip an easy and comfortable
handling (Richard Wolf GmbH, Knittlingen, Germany).
The maximal outer diameter of the oval-shaped shaft is
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6.3mm. A 258 optic is available for use in specific
situations.
The camera used is the Stereositee (Vista Medical
Technologies Inc., Carlsbad, California, USA). This
camera system incorporates a Head-Mounted Display
(HMD) that is worn by the surgeon during all phases
of the operation. The endoscopic picture is projected
on LCD-screens from the HMD with a resolution of
640 * 480 pixels. The instruments used are principally
the same as those used during a conventional microsur-
gical procedure.
In cases where the tumor is identified by MRI or
during the operation, selective adenomectomy is per-
formed. In case of negative MRI investigations and a
negative pituitary exploration, a hemihypophysectomy
is performed, preferentially based on lateralization of
ACTH levels during inferior petrosal sinus sampling.
Only in cases of persisting hypercortisolism after sur-
gery, a total adenohypophysectomy is performed in a
second surgical procedure.
Postoperative evaluation
The early postoperative biochemical evaluation con-
sisted of measuring the fasting (0800 h) plasma levels
of ACTH and cortisol on the seventh day after surgery
(48 h after the last dose of glucocorticoids). In patients
with a basal plasma cortisol concentration below
200nmol/L substitution therapy with hydrocortisone,
30mg once daily, or cortisone acetate, 37.5mg once
daily, was prescribed. Patients were re-evaluated every
24 weeks during the first 3 months and thereafter at
2–3 months intervals during the first year after sur-
gery and at least yearly thereafter. At each visit the fast-
ing plasma cortisol concentration was measured after
withdrawal of glucocorticoid substitution for 24 h. In
addition, a low dose dexamethasone suppression test
(1mg overnight) was performed at 1 and 3 months
after surgery. In every patient in whom glucocorticoid
substitution was started after surgery, we tried to
reduce the dose of oral glucocorticoids starting 3
months after surgery and to stop glucocorticoid substi-
tution within 12 months after surgery. After stopping
glucocorticoid substitution the integrity of the hypo-
thalamic-pituitary-adrenal axis was assessed in these
patients by the insulin-hypoglycemia test (40). In all
patients who were in remission of hypercortisolism
after pituitary surgery, low dose dexamethasone sup-
pression tests (1mg overnight) were performed yearly
and of course earlier when there was a clinical suspi-
cion of recurrence of the hypercortisolism.
Assessment of the thyrotropic, gonadotropic and
somatotropic axis was performed at regular intervals
by measuring the serum concentrations of thyrotropin
(TSH), free thyroxine (FT4), gonadotropins (LH and
FSH), testosterone, estradiol and insulin-like growth
factor- 1 (IGF-1). In case of clinical suspicion of
growth hormone (GH) deficiency a GH stimulation
test (preferably an insulin-hypoglycemia test) was
performed.
Criteria for remission and relapse
Remission was defined as adequate suppression of
plasma cortisol (#50nmol/L) after 1mg dexametha-
sone overnight determined in the first 3 months after
surgery and disappearance of clinical signs and symp-
toms of hypercortisolism.
Relapse was defined as development of inadequate
suppression of plasma cortisol after 1mg dexametha-
sone overnight in a patient who was postoperatively
in remission according to the above-mentioned criteria.
Assays
ACTH was measured in EDTA plasma by a two-step
immunoradiometric assay (IRMA, Dynotest BRAHMS,
Berlin, Germany). Within and between assay coeficients
of variations (CV) were 5.8% and 7.4% at a level
of 2.4 pmol/L and 4.7% and 4.0% at a level of
29.9 pmol/L. A functional detection limit of 0.8 pmol/L
was established. The reference range is 2.2–
13.2 pmol/L.
Plasma cortisol was measured by radioimmunoassay.
In patients who were treated with metyrapone and/or
ketoconazole the radioimmunoassay was done after
previous extraction and paper chromatography (41).
To summarize briefly, before extraction 3H-cortisol
was added to correct for procedural losses. After chro-
matography, the location of the cortisol zone was ident-
ified by radiochromatogram scanning, the zone was cut
out and soaked in buffer. The recovered radioactivity
was measured by liquid scintillation counting of an ali-
quot from the eluate. Subsequently, cortisol tracer and
antiserum were added and after incubation, free and
bound tracers were separated by means of dextran
coated charcoal. The antibody bound radioactivity
was assessed by liquid scintillation counting of the
supernatant. The calculations were performed by
special software designed for correction of the mass
and radioactive contribution of the recovery tracer in
the RIA. Using a sample volume of 0.05ml, the detec-
tion limit was 1.4 nmol/L. The between-assay CV was
5.9% at a level of 320 nmol/L. Accuracy was assessed
over a longer period of time by measurement of QC
samples in which the cortisol levels had been estab-
lished by GC/MS, which resulted in 100.7^2.4%
(n ¼ 40) of the target value.
The reference range is 190–500 nmol/L (at 0800h).
Statistics
Chi-square tests were used to test for differences in the
proportion of patients with macroadenomas, histologi-
cal confirmation of the ACTH producing adenoma and
use of cortisol lowering medication between the
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remission and failure groups. Statistical significance
was considered when P , 0.05 (two-tailed).
Results
The results of endoscopic transsphenoidal pituitary sur-
gery in the 35 patients with Cushing’s disease are
shown in Fig. 1. The individual data of the 35 patients
are given in Table 1. The mean follow-up was 27
months (range 4 to 81 months; median 20 months).
After initial pituitary surgery 25 patients were in remis-
sion according to the criteria mentioned above. In two
patients (patients 7 and 17) a 1mg dexamethasone
suppression test was not done postoperatively. However,
both had a clearly subnormal basal cortisol level post-
operatively and went into clinical remission and still
received glucocorticoid substitution at the last follow-
up visit. Including these two patients the remission
rate in our series was 77%. During the follow-up
none of the patients in our series had a relapse of Cush-
ing’s syndrome. In 8 patients initial pituitary surgery
failed to cure the hypercortisolism. In three of these
patients (patients 6, 10 and 11) the tumor could not
be localized, either preoperatively on MRI or during
pituitary surgery, and one patient (patient 18) had a
lesion suspect for a microadenoma on the preoperative
MRI. No ACTH producing adenoma was found on his-
tological examination of tissue removed during the first
surgery in these four patients. Three of them (patients
6, 10 and 11) had a second endoscopic pituitary oper-
ation between 3 and 11 months after the initial sur-
gery. In none of these patients histological
examination of the tissue removed during the second
operation showed evidence of an ACTH producing ade-
noma. Nevertheless, two of them became in remission
after the second operation (patients 6 and 10). In the
third patient hypercortisolism persisted after the
second operation and she finally had a bilateral adrena-
lectomy eight months later (patient 11). In the fourth
patient (patient 18) the second pituitary surgery will
soon follow. Four other patients with a failure of the
first pituitary operation were treated postoperatively
with radiotherapy (patients 4, 9, 21 and 34). Two of
these patients had macroadenomas with invasion of
the cavernous sinus (patients 9 and 21) and one had
a microadenoma on the MRI (patient 4). In one patient
the tumor could not be visualized either on the MRI, or
during the exploration of the pituitary (patient 34). The
presence of an ACTH producing adenoma was con-
firmed on histological examination in the three patients
in whom the tumor was visualized. At the time of the
last follow-up visit (45 and 34 months after radiother-
apy), two of these patients (patients 4 and 9) were in
remission. The second patient with a macroadenoma
is improving clinically after radiotherapy. At the
moment (11 months after radiotherapy) he uses
ketoconazole in decreasing dosage (patient 21). The
fourth patient has only recently received radiotherapy
and is still receiving ketoconazole (patient 34).
As can be seen in Table 1, there was a gradual
increase in the number of patients receiving endoscopic
surgery per year. During the first four years after the
introduction of the endoscopic technique, in 6 out of
10 patients (60%) a remission was achieved after initial
pituitary surgery. However, in the following three years
a remission was achieved in 21 of the 25 patients
(84%). Remission was achieved in 29 patients (83%)
after the first or second pituitary surgery. There have
been no recurrences in these 29 patients during
follow-up.
When comparing the groups of patients with suc-
cessful and unsuccessful initial pituitary surgery, a
macroadenoma was present in 25% of the patients
with unsuccessful and in 14% of the patients with suc-
cessful surgery (P ¼ 0.37), whilst the percentage of
patients that were treated preoperatively with cortisol
lowering agents was the same (85.5% in both
groups). The percentage of patients in whom the pre-
sence of an ACTH producing adenoma was confirmed
histologically was 81% in the succesfully compared to
50% in the unsuccesfully operated patients
(P ¼ 0.061).
Ten of the 27 patients who had a successful initial
surgery had complications perioperatively. Two patients
remission
N=27
remission
N=2
ADX
N=1
surgery follows
N=1
2-nd pituitary surgery
N=4
remission
N=2
ketoconazole
N=2
Radiotherapy
N=4
failure
N=8
Endoscopic pituitary surgery for Cushing's disease
N=35
Figure 1 Results of endoscopic pituitary surgery in patients with Cushing’s disease (1998–2004). (ADX: bilateral adrenalectomy).
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Table 1 Clinical characteristics of the 35 consecutive patients with Cushing’s disease operated by endoscopic transsphenoidal pituitary surgery between 1998 and 2004.
Cortisol (nmol/L)
Patient no., gender,
age (years) CLA MRI SPS Year of TS Histology Basal After Dex TS result Additional therapy Hormona substitution
Follow-up
(months)
1. m, 35 M – left 1998 þ ,20 ,20 R – – 81
2. f, 22 K ,10 left 1998 þ 30 – R – E, GH, T 81
3. f, 46 M – NP 1998 þ ,20 40 R – – 74
4. f, 42 M ,10 NP 2000 þ 560 200 F CR (45 Gy) G, GH 57
5. f, 32 – – NP 2000 – 70 ,20 R – E 50
6. f, 45 K – right 2000 – 440 430 F TS E, G, T 49
7. f, 44 M ,10 NP 2001 þ 80 – R – G 24†
8. f, 51 – – right 2001 þ 70 40 R – – 41
9. m, 23 – 18 NP 2001 þ 280 70 F RS (20 Gy) T 39
10. m, 29 M – left 2001 – 270 110 F TS A, G, T 37
11. f, 36 M, K – right 2002 – 400 530 F TS, ADX G, T 35
12. m, 23 – 35 NP 2002 þ 110 20 R – – 33
13. f, 62 K ,10 NP 2002 þ ,20 – R – G, D 31
14. f, 22 – – NP 2002 þ 20 ,20 R – E 27
15. f, 31 K ,10 NP 2002 þ 40 – R – G, T 25
16. m, 63 M ,10 NP 2002 þ ,20 20 R – A 25
17. f, 37 K ,10 right 2003 – 70 – R – G 22
18. f, 20 M ,10 right 2003 – 90 140 F TS follows – 20
19. f, 41 M, K ,10 left 2003 þ 350 20 R – – 18
20. f, 49 M 18 NP 2003 þ 190 50 R – – 17
21. m, 39 M 12 NP 2003 þ 290 110 F RS (35 Gy) – 17
22. m, 14 M ,10 left 2003 – 20 30 R – T 14
23. f, 66 M ,10 NP 2003 þ 150 30 R – G 13
24. f, 55 M ,10 NP 2003 þ 90 ,30 R – T, D 12
25. m, 38 M – left 2004 – 200 ,20 R – T 11
26. f, 55 K 17 NP 2004 þ 90 ,30 R – G 10
27. f, 68 K ,10 NP 2004 þ 270 40 R – G 9
28. f, 64 M ,10 NP 2004 þ 560 ,20 R – – 9
29. f, 53 M, K – NP 2004 – 300 20 R – – 8
30. f, 37 K – NP 2004 þ 320 20 R – – 8
31. f, 32 M ,10 NP 2004 þ ,20 – R – G, T 6
32. f, 55 M ,10 NP 2004 þ 30 – R – G, T 6
33. f, 30 M ,10 NP 2004 þ 60 40 R – G, T 4
34. m, 55 M – left 2004 – 470 160 F RS (19 Gy) – 4
35. m, 21 M 20 NP 2004 þ 90 50 R – – 4
f: female; m: male; CLA: preoperative therapy with cortisol lowering agents; M: metyrapone; K: ketoconazole; MRI: magnetic resonance imaging results given as maximal diameter of the visualized tumor in
mm, MRI-: no tumor visualized on the MRI; SPS: sampling of inferior petrosal sinuses; left: lateralisation to the left inferior petrosal sinus; right: lateralisation to the right petrosal sinus; NP; not performed;
Histology þ : evidence of ACTH producing adenoma on histological examination; Histology 2 : no evidence of ACTH producing adenoma on histological examination; Cortisol basal: fasting plasma cortisol
level at 0800 h on the seventh day after surgery (48 h after the last dose of glucocorticoids); after Dex: plasma cortisol level at 0800 h after 1 mg dexamethasone overnight; TS: endoscopic transsphenoidal
pituitary surgery; R: remission; F: failure; CR: conventional radiotherapy; RS: radiosurgery; ADX: bilateral adrenalectomy; A: androgens, D: desmopressin; E: estrogens, G: glucocorticoids, GH: growth hor-
mone; T: levothyroxine; †patient deceased.
E
n
doscopic
su
rgery
for
C
u
sh
in
g’s
disease
6
7
9
E
U
R
O
P
E
A
N
JO
U
R
N
A
L
O
F
E
N
D
O
C
R
IN
O
L
O
G
Y
(2
0
0
6
)
1
5
4
w
w
w
.e
je
-o
n
lin
e
.o
rg
had mild epistaxis controlled with nasal tampons
(patients 12 and 25). In one patient (patient 13), a
bleeding originating in the sphenopalatinal artery
occurred postoperatively. This required a second
exploration with successful coagulation of the artery.
In this patient bleeding was not present at the end of
the first surgery, most likely due to vasoconstriction
by injection of epinephrine around the sphenoid
ostium. The patient recovered within a few days after
the second operation without other complications.
Three patients had mild cerebrospinal fluid (CSF) leak-
age that resolved spontaneously in two of them within
a few days (patients 3 and 23) and in the third patient
CSF drainage was performed using a lumbal external
drain (patient 22). There were two episodes of sudden
drop in blood pressure that occurred one week after
surgery (patients 23 and 32) caused by glucocorticoid
deficiency as both patients were at that time 48h
after withdrawal of glucocorticoids and they both
recovered shortly after administration of glucocorti-
coids. Three additional patients received transiently
desmopressin due to polyuria that resumed after the
first days postoperatively. One patient developed mild
hyponatremia two weeks after surgery, probably due
to a combination of inappropriate ADH secretion and
concomitant use of thiazide diuretics. This resolved
within two days after the diuretics were discontinued
and after starting water restriction. There has been
no complication in the failure group.
According to the last follow-up data, 22 (17 from the
remission group and 5 from the failure group) of the 35
patients received substitution therapy for deficiency of
one or more hormones. These data are summarized
in Table 1. Of all patients, 34% required substitution
with levothyroxine, 40% required substitution with
glucocorticoids, 17% received estrogens or testosterone
and 5.7% still required desmopressin. Six of the 14
patients still using glucocorticoids had a follow-up of
less than 18 months with glucocorticoid dosages still
being tapered, so a definitive statement of their adrenal
function cannot yet be made.
Discussion
In the present study we report the results of endoscopic
pituitary surgery in 35 consecutive patients with Cush-
ing’s disease operated in our centre. In our seven years
experience, remission of hypercortisolism was achieved
in 77% of the patients after the first pituitary operation
and in 83% of the patients after the first and the second
pituitary operation taken together. This is the largest
reported series of endocrinological results in patients
with Cushing’s disease operated via the endoscopic
technique.
Due to its recent introduction, there are only few
reports describing larger series of patients with pitu-
itary tumors operated via the endoscopic technique
(25, 29, 35). It seems that the endocrine outcomes of
the patients reported in these initial series are similar
to those achieved by the conventional microscopic tech-
nique. Cappabianca et al.(29) reported on 87 patients
with various pituitary adenomas, including 8 patients
with Cushing’s disease, that were treated with endo-
scopic endonasal transsphenoidal pituitary surgery
between 1997 and 1999. As remission criterion for
patients with Cushing’s disease the authors adopted a
restoration of the circadian rhythm of cortisol together
with the normalization of urinary cortisol levels. Three
of these 8 patients had a macroadenoma, one of whom
showed parasellar extension with incomplete third cra-
nial nerve palsy. Among the patients with a microade-
noma, one underwent a second operation one day after
the first surgery because of residual tumor detected on
the MRI. Only one patient (having a microadenoma) of
this series remained hypercortisolemic after the pitu-
itary operation and was treated additionally by bilateral
adrenalectomy. The authors reported no complications
during or after surgery in the patients with Cushing’s
disease. Jho et al. (25) reported in a series of 128
patients with pituitary adenomas operated by endo-
scopic transsphenoidal surgery, including 16 patients
with Cushing’s disease, that 70% of the patients with
Cushing’s disease had a (sub-)normal postoperative cor-
tisol level. Although these results seem promising, the
number of patients with Cushing’s disease in these
series was too small and postoperative biochemical
evaluation was not extensive.
The short follow-up of the patients in our series, due
to the recent introduction of the endoscopic technique
in the field of pituitary surgery, does not allow us to
make any comments on the long-term remission rates
of our patients. As previously shown in other series of
patients with Cushing’s disease, recurrences may
develop many years after apparently successful surgical
treatment (1–3, 5, 7–10, 12–15). However, our early
postoperative results of endoscopic pituitary surgery in
a large number of patients with Cushing’s disease are in
line with the previous studies, reporting on smaller
number of patients (25, 29, 35) and with the results
of other large single center series of patients operated
by traditional transsphenoidal pituitary microsurgery
previously reported (Table 2). Early postoperative cure
rates ranging from 68.5 to 87% have been reported
in those large series (1–3, 5, 7–10, 12–15). These
differences in remission rates can be at least, in part
explained by the different remission criteria used in
those studies. Based on the principle that high preo-
perative plasma cortisol levels suppress normal cortico-
troph cell function and that complete removal of a
corticotroph adenoma will render the patient ACTH
deficient with low to undetectable cortisol levels post-
operatively, some authors have adopted as criterion
for remission a postoperative plasma cortisol value of
,50nmol/L (3, 12, 42). However Yap et al. (3)
showed that even a cortisol level ,50nmol/l early
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Table 2 Review of the criteria used to define remission of Cushing’s disease after pituitary surgery in the most recent published single centre series (1995–2004).
Author Single surgeon N Remission criteria Perioperative G regimen Remission %
Sonino, 1996 (14) Yes 103 Regression of clinical signs, UFC ,248 nmol/l and
suppressable C (reference not mentioned) to low dose
Dex 5–15 days from TS at least 24 h after G withdrawal.
Not mentioned 76.7
Petruson, 1997 (4) No 31 24-h UFC ,300 nmol/ day and normal circadian rhythm
of serum C, including a midnight value ,150 nmol/l within
5 weeks from TS and 48 h after G withdrawal.
100 mg HC i.v. on day 1 and 50 mg/day
CA for the next 7 days
77
Estrada, 1997, 2001 (10, 45) Yes 82 Normal UFC , 331 nmol/24 h, adequate suppression
of plasma C to overnight 1 mg Dex (,5 ug/dl, 138 nmol/l),
8 to 12 days after TS, 24 h after G withdrawal.
300 mg HC on TS day, gradually reduced
till hormonal evaluation.
75.5
Blevins, 1998 (6) Not mentioned 96 Basal C ,5 ug/dl or UFC ,15ug/24 h, or suppression
of plasma and urinary C to Dex within 6 months after TS.
Not mentioned 85.6
Swearingen, 1999 (15) No 154 Fasting serum C ,138 nmol/l and UFC ,55 nmol/l
within 10 days after TS.
Not mentioned 87
Chee, 2001 (2) Yes 61 Resolution of clinical signs, suppression of
C , 100 nmol/l after 1.5–2 mg Dex overnight and
reduction of C to normal range for both morning
and midnight values, 48 h after G withdrawal, within
5 days after TS.
Not mentioned 78.7
Yap, 2002 (3) Yes 97 Basal C , 50 nmol/l 3–4 days after TS, 24-h after
G withdrawal.
Not mentioned 68.5
Rees, 2002 (12) No 54 Basal C , 50 nmol/l within 1 week from TS,
24 h after G withdrawal.
100 mg/6 h HC i.v. on day 1,
thereafter HC substitution.
77
Pereira, 2003 (1) Yes 78 Regression of clinical signs, suppression
of C ,100 nmol/l to 1 mg Dex and normal 24-h
UFC 6 months after TS.
1 mg/12 h Dex on day 1, gradually
reduced to 0.5 mg/day on day 5.
72
Rollin, 2004 (13) Yes 41 Clinical remission, G dependence, serum
C , 3 ug/dl (82,8 nmol/l) after overnight 1 mg
Dex within 10–12 days after TS.
HC 100 mg i.v intraoperatively and 50 mg/6 h for 48 h,
followed by prednisone 5 mg/day for 5–6 days
(17 TS) and no G substitution (28 TS).
85.3
Hammer, 2004 (5) Yes 289 Basal or 1 mg Dex suppressed C , 140 nmol/l within
1 week from TS or low/normal plasma C and UFC
and no additional therapy within 6 months.
Not mentioned. 82
C: cortisol; Dex: dexamethasone; HC: hydrocortisone; CA: cortisone acetate; TS transsphenoidal pituitary surgery; G: glucocorticoids; UFC: urinary fractionated cortisol excretion.
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after surgery does not always predict the long-term
remission of Cushing’s disease. Interestingly, Pereira
et al. (1) recently found that a fasting cortisol level
,138nmol/L measured 3 months after the operation
is a stronger predictor for long-term relapse than a
plasma cortisol level ,50nmol/L measured early post-
operatively. As most of our patients were treated preo-
peratively with cortisol lowering medication, that
renders them less prone to hypocortisolism early post-
operatively, we adopted as biochemical remission cri-
terion in these patients suppression of the plasma
cortisol level to 1mg dexamethasone overnight.
The endoscopic technique requires the use of refined
instruments, specific skills of the pituitary surgeon and
a learning curve (20). In our centre endoscopic pitu-
itary surgery was introduced in 1997 but it has been
applied in patients with Cushing’s disease only since
1998. All operations were performed by the same two
experienced neurosurgeons who both were already
very familiar with the endoscopic technique. As the
number of patients with Cushing’s disease operated
per year increased, the neurosurgery team became
more experienced and the number of ‘failures’
decreased (success percentages 60% in patients oper-
ated between 1998 and 2001 versus 88% in patients
operated between 2002 and 2004). As in other studies
(6, 43, 44), we found that the remission percentages
were worse in patients with a macroadenoma (66%
vs 79% in patients with microadenoma) and in those
who did not have an ACTH producing adenoma
proven on pathology (50% vs 84% in patients with
positive pathology findings). While the endoscopic tech-
nique offers advantages in removing macroadenomas
due to the wide-angle view, one might argue on optical
grounds that it would be more difficult to discriminate
the microadenomas from the surrounding tissue than
when using the binocular microscopic technique. How-
ever, apart from the optics other factors may contribute
as well to the successful identification and removal of
microadenomas by endoscopy, e.g. the superior illumi-
nation of the surgical field. In addition, the increased
elevation of the patients head and trunk during endo-
scopic surgery may decrease venous bleeding during
surgery, providing thus a better visualization of the sur-
gical field. Our results show that, in the hands of experi-
enced neurosurgeons, similar remission percentages
were obtained in patients with both macro- and micro-
adenomas as in previously reported series of patients
with Cushing’s disease operated by the conventional
microscopic technique (1–3, 5, 7–10, 12–15).
In our series there were only few serious surgical
complications postoperatively. One serious bleeding
requiring a reoperation took place and only one patient
had CSF leakage requiring a lumbal external drain,
which is similar to the experience of Hammer et al.
(5) in their series of 289 patients with Cushing disease
treated by conventional microscopic transsphenoidal
surgery, in which 13 patients required a drain or surgi-
cal repairment for CSF leakage (5). An important
aspect that needs to be stressed when comparing the
frequency of complications reported in various studies
(1–3, 5, 7–10, 12–15) is that, in these studies, differ-
ent definitions are used for each complication. More-
over, as all of these studies report retrospective
results, one must be careful in interpreting and compar-
ing these results that basically rely on the accuracy by
which the complications were recorded in each individ-
ual patient.
We cannot make a statement on whether applying
the endoscopic technique can modify the postoperative
hospitalization time. The protocol used in our hospital,
both before and after the introduction of endoscopic
pituitary surgery, is that all patients treated for Cush-
ing’s disease remain under clinical observation for 7
days until the early postoperative endocrine evaluation
has taken place. In this way we ensured a uniform and
objective early postoperative observation and regis-
tration of postoperative events.
In our series the surgery was as selective as possible
in order to avoid damaging of normal pituitary tissue.
Nevertheless, 63% of the patients required hormonal
substitution therapy with one or more preparations at
the time of last follow-up, including those requiring
temporary glucocorticoid substitution. When patients
requiring only glucocorticoid replacement therapy
were excluded, hypopituitarism, defined as proven
deficiency of at least one of the pituitary hormones,
was present in 48% of the patients. However, 6 of the
14 patients who received substitution therapy with glu-
cocorticoids at the time of data collection were in the
process of decreasing their glucocorticoid substitution.
In addition 5 of the patients who were receiving substi-
tution therapy at the time of the last follow-up had a
failure of the first pituitary surgery and were treated
subsequently with more extensive surgery or additional
radiotherapy. Furthermore, there seemed to be more
combined hormone deficiencies in the patients operated
in the early years (1998–2001). Our data on post-
operative pituitary insufficiency are in keeping with
results of previously reported series of patients operated
by the conventional microscopic technique (2, 3, 8, 12,
15, 42). The rate of hypopituitarism defined as at least
one deficient pituitary hormone axis after pituitary sur-
gery ranges from 14–62% in these previous reports
and seems to be related to more extensive surgical
approaches.
In our study, inferior petrosal sinuses sampling was
not performed in order to identify the side of the pitu-
itary where the adenoma is located, but to confirm
the pituitary origin of the hypercortisolism in patients
with equivocal results of initial endocrine function
tests, regardless the findings on MRI. Only in case of
negative MRI investigations and a negative pituitary
exploration, a hemihypophysectomy was performed,
based on results of ACTH levels at the right and at
the left side during inferior petrosal sinus sampling, if
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available. The same strategy has been previously used
in other reported series (5).
In conclusion, endoscopic transsphenoidal pituitary
surgery, in the hands of experienced surgeons, resulted
in our series of patients with Cushing’s disease in an
excellent early postoperative remission rate which was
as good as those previously reported by experienced
centres using conventional microscopic techniques.
Surgical complications and discomfort for the patients
were minimal. The question that remains to be
answered is whether endoscopic pituitary surgery will
also result in a favourable long-term outcome of
patients with Cushing’s disease. Furthermore, a ran-
domized clinical trial, comparing endoscopic and con-
ventional pituitary surgery in patients with Cushing’s
disease, is needed to determine the pros and cons of
both techniques.
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